BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 28120942)

  • 1. The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene.
    Tormo E; Adam-Artigues A; Ballester S; Pineda B; Zazo S; González-Alonso P; Albanell J; Rovira A; Rojo F; Lluch A; Eroles P
    Sci Rep; 2017 Jan; 7():41309. PubMed ID: 28120942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells.
    Ichikawa T; Sato F; Terasawa K; Tsuchiya S; Toi M; Tsujimoto G; Shimizu K
    PLoS One; 2012; 7(2):e31422. PubMed ID: 22384020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic microRNA activity identifies therapeutic targets in trastuzumab-resistant HER2
    Decker JT; Hall MS; Blaisdell RB; Schwark K; Jeruss JS; Shea LD
    Biotechnol Bioeng; 2018 Oct; 115(10):2613-2623. PubMed ID: 29981261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-126 reduces trastuzumab resistance by targeting PIK3R2 and regulating AKT/mTOR pathway in breast cancer cells.
    Fu R; Tong JS
    J Cell Mol Med; 2020 Jul; 24(13):7600-7608. PubMed ID: 32410348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer.
    Gong C; Yao Y; Wang Y; Liu B; Wu W; Chen J; Su F; Yao H; Song E
    J Biol Chem; 2011 May; 286(21):19127-37. PubMed ID: 21471222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R.
    Ye XM; Zhu HY; Bai WD; Wang T; Wang L; Chen Y; Yang AG; Jia LT
    BMC Cancer; 2014 Feb; 14():134. PubMed ID: 24571711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
    De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
    Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
    Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
    Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Antitumor Effect of Metformin Is Mediated by miR-26a in Breast Cancer.
    Cabello P; Pineda B; Tormo E; Lluch A; Eroles P
    Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27517917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer.
    Palomeras S; Diaz-Lagares Á; Viñas G; Setien F; Ferreira HJ; Oliveras G; Crujeiras AB; Hernández A; Lum DH; Welm AL; Esteller M; Puig T
    Breast Cancer Res; 2019 Jul; 21(1):79. PubMed ID: 31277676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.
    Venturutti L; Cordo Russo RI; Rivas MA; Mercogliano MF; Izzo F; Oakley RH; Pereyra MG; De Martino M; Proietti CJ; Yankilevich P; Roa JC; Guzmán P; Cortese E; Allemand DH; Huang TH; Charreau EH; Cidlowski JA; Schillaci R; Elizalde PV
    Oncogene; 2016 Dec; 35(48):6189-6202. PubMed ID: 27157613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
    Zhang Z; Zhang L; Yu G; Sun Z; Wang T; Tian X; Duan X; Zhang C
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):761-772. PubMed ID: 33068176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance.
    Rezaei Z; Sebzari A; Kordi-Tamandani DM; Dastjerdi K
    DNA Cell Biol; 2019 Feb; 38(2):184-192. PubMed ID: 30702337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells.
    Boulbes DR; Chauhan GB; Jin Q; Bartholomeusz C; Esteva FJ
    Breast Cancer Res Treat; 2015 Jun; 151(3):501-13. PubMed ID: 25971596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-129-5p Sensitizes the Response of Her-2 Positive Breast Cancer to Trastuzumab by Reducing Rps6.
    Lu X; Ma J; Chu J; Shao Q; Zhang Y; Lu G; Li J; Huang X; Li W; Li Y; Ling Y; Zhao T
    Cell Physiol Biochem; 2017; 44(6):2346-2356. PubMed ID: 29258115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer stem cells are involved in Trastuzumab resistance through the HER2 modulation in 3D culture.
    Rodríguez CE; Berardi DE; Abrigo M; Todaro LB; Bal de Kier Joffé ED; Fiszman GL
    J Cell Biochem; 2018 Feb; 119(2):1381-1391. PubMed ID: 28722778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The microRNA-141-3p/ CDK8 pathway regulates the chemosensitivity of breast cancer cells to trastuzumab.
    Song W; Wu S; Wu Q; Zhou L; Yu L; Zhu B; Gong X
    J Cell Biochem; 2019 Aug; 120(8):14095-14106. PubMed ID: 31087707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
    Takeda T; Yamamoto H; Kanzaki H; Suzawa K; Yoshioka T; Tomida S; Cui X; Murali R; Namba K; Sato H; Torigoe H; Watanabe M; Shien K; Soh J; Asano H; Tsukuda K; Kitamura Y; Miyoshi S; Sendo T; Toyooka S
    PLoS One; 2017; 12(2):e0171356. PubMed ID: 28158234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells.
    Yang L; Li Y; Shen E; Cao F; Li L; Li X; Wang X; Kariminia S; Chang B; Li H; Li Q
    Int J Oncol; 2017 Nov; 51(5):1553-1562. PubMed ID: 29048656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer.
    Sabbaghi M; Gil-Gómez G; Guardia C; Servitja S; Arpí O; García-Alonso S; Menendez S; Arumi-Uria M; Serrano L; Salido M; Muntasell A; Martínez-García M; Zazo S; Chamizo C; González-Alonso P; Madoz-Gúrpide J; Eroles P; Arribas J; Tusquets I; Lluch A; Pandiella A; Rojo F; Rovira A; Albanell J
    Clin Cancer Res; 2017 Nov; 23(22):7006-7019. PubMed ID: 28821558
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.